Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)Business Wire • 10/30/20
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial ResultsBusiness Wire • 10/22/20
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney WeekBusiness Wire • 10/22/20
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?The Motley Fool • 10/18/20
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age GroupsBusiness Wire • 10/16/20
Alnylam Reports Another Positive Study Outcome, Securing More Of Its Future Revenue GrowthSeeking Alpha • 09/30/20
Alnylam Pharmaceuticals Posts Positive Results For Its Treatment For Rare DiseaseInvestors Business Daily • 09/30/20
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of SixBusiness Wire • 09/30/20
Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines ConferenceBusiness Wire • 09/28/20
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi RoundtableBusiness Wire • 09/03/20
Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular DiseaseBusiness Wire • 08/17/20
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/06/20